<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab2">
 <label>Table 2</label>
 <caption>
  <p>A summary of several aptamers developed for the treatment of viral infections by SELEX method</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Organism</th>
    <th>Type of aptamer</th>
    <th>Target</th>
    <th>Aptamer therapeutic effect</th>
    <th>Ref</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>HBV</td>
    <td>DNA</td>
    <td>Core protein</td>
    <td>
     <p>-Prevent the assembly of the nucleocapsid</p>
     <p>-function by suppressing HBV replication</p>
    </td>
    <td>[
     <xref ref-type="bibr" rid="CR82">82</xref>]
    </td>
   </tr>
   <tr>
    <td>HCV</td>
    <td>DNA</td>
    <td>Envelope Protein</td>
    <td>-Inhibition of virus binding to host cells</td>
    <td>[
     <xref ref-type="bibr" rid="CR90">90</xref>]
    </td>
   </tr>
   <tr>
    <td>Influenza A virus</td>
    <td>DNA</td>
    <td>Hemagglutinin protein</td>
    <td>
     <p>-Blocking the binding of</p>
     <p>virus to target cell receptors</p>
     <p>-prevention of the virus invasion into the host cells</p>
    </td>
    <td>[
     <xref ref-type="bibr" rid="CR83">83</xref>]
    </td>
   </tr>
   <tr>
    <td>Ebola Virus</td>
    <td>RNA</td>
    <td>VP35</td>
    <td>-Disrupt the eVP35âˆ’ NP interaction</td>
    <td>[
     <xref ref-type="bibr" rid="CR91">91</xref>]
    </td>
   </tr>
   <tr>
    <td>HIV-1</td>
    <td>RNA</td>
    <td>gag protein</td>
    <td>-Inhibit HIV-1 replication</td>
    <td>[
     <xref ref-type="bibr" rid="CR92">92</xref>]
    </td>
   </tr>
   <tr>
    <td>HSV-1</td>
    <td>RNA</td>
    <td>gD protein</td>
    <td>-Blocking the gD functions</td>
    <td>[
     <xref ref-type="bibr" rid="CR85">85</xref>]
    </td>
   </tr>
   <tr>
    <td>Vaccinia virus</td>
    <td>DNA</td>
    <td>Hemagglutinin protein</td>
    <td>
     <p>-Recognize proteins</p>
     <p>expressed on the surface of VV- infected cells</p>
    </td>
    <td>[
     <xref ref-type="bibr" rid="CR93">93</xref>]
    </td>
   </tr>
   <tr>
    <td>Influenza B Virus</td>
    <td>RNA</td>
    <td>Hemagglutinin protein</td>
    <td>-Inhibited HA-mediated membrane fusion</td>
    <td>[
     <xref ref-type="bibr" rid="CR94">94</xref>]
    </td>
   </tr>
   <tr>
    <td>SCV</td>
    <td>RNA</td>
    <td>nsP10</td>
    <td>-Inhibit double-stranded DNA unwinding activity of the helicase</td>
    <td>[
     <xref ref-type="bibr" rid="CR89">89</xref>]
    </td>
   </tr>
   <tr>
    <td>Rabies virus</td>
    <td>DNA</td>
    <td>
     <p>Blocking the interaction</p>
     <p>between rabies virus and permissive host cell receptors</p>
    </td>
    <td>-Reduced viral replication in an in vitro infection model</td>
    <td>[
     <xref ref-type="bibr" rid="CR84">84</xref>]
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>
   <italic>VP35</italic> viral protein 35, 
   <italic>NP</italic> nucleoprotein, 
   <italic>nsP10</italic> NTPase/Helicase
  </p>
 </table-wrap-foot>
</table-wrap>
